Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart C Gordon

Showing results (171-180 of 214) with videos related to

Pageof 22
Sort By:
Clinical Epidemiology|November 18, 2020
Validity of an Automated Algorithm to Identify Cirrhosis Using Electronic Health Records in Patients with Primary Biliary CholangitisMei Lu, Christopher L Bowlus, Keith Lindor, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 4, 2014
Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log10 copies/ml)Scott Fung, Stuart C Gordon, Zahary Krastev, et al.
Journal of Hepatology|March 4, 2015
The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infectionEdward J Gane, Young-Suk Lim, Stuart C Gordon, et al.
Journal of Hepatology|March 20, 2018
High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosisMassimo Puoti, Graham R Foster, Stanley Wang, et al.
Hepatology (Baltimore, Md.)|November 21, 2017
Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failureFred Poordad, Stanislas Pol, Armen Asatryan, et al.
Journal of Hepatology|December 3, 2015
Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patientsW Ray Kim, Thomas Berg, Tarik Asselah, et al.
Gastroenterology|May 26, 2012
Factors that predict response of patients with hepatitis C virus infection to boceprevirFred Poordad, Jean-Pierre Bronowicki, Stuart C Gordon, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 27, 2017
Increasing Prevalence of Primary Biliary Cholangitis and Reduced Mortality With TreatmentMei Lu, Yueren Zhou, Irina V Haller, et al.
Hepatology Communications|April 13, 2026
Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studiesStuart C Gordon, Alejandra Villamil, Ira M Jacobson, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 11, 2026
Gaps in Guideline Adherence for Primary Sclerosing Cholangitis in North America-A 5-Year AnalysisAdrielly Martins, Anish Reddy, Richard Dean, et al.
Pageof 22

Showing results (171-180 of 214) with videos related to

Sort By:
Pageof 22
Clinical Epidemiology|November 18, 2020
Validity of an Automated Algorithm to Identify Cirrhosis Using Electronic Health Records in Patients with Primary Biliary CholangitisMei Lu, Christopher L Bowlus, Keith Lindor, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 4, 2014
Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log10 copies/ml)Scott Fung, Stuart C Gordon, Zahary Krastev, et al.
Journal of Hepatology|March 4, 2015
The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infectionEdward J Gane, Young-Suk Lim, Stuart C Gordon, et al.
Journal of Hepatology|March 20, 2018
High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosisMassimo Puoti, Graham R Foster, Stanley Wang, et al.
Hepatology (Baltimore, Md.)|November 21, 2017
Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failureFred Poordad, Stanislas Pol, Armen Asatryan, et al.
Journal of Hepatology|December 3, 2015
Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patientsW Ray Kim, Thomas Berg, Tarik Asselah, et al.
Gastroenterology|May 26, 2012
Factors that predict response of patients with hepatitis C virus infection to boceprevirFred Poordad, Jean-Pierre Bronowicki, Stuart C Gordon, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 27, 2017
Increasing Prevalence of Primary Biliary Cholangitis and Reduced Mortality With TreatmentMei Lu, Yueren Zhou, Irina V Haller, et al.
Hepatology Communications|April 13, 2026
Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studiesStuart C Gordon, Alejandra Villamil, Ira M Jacobson, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 11, 2026
Gaps in Guideline Adherence for Primary Sclerosing Cholangitis in North America-A 5-Year AnalysisAdrielly Martins, Anish Reddy, Richard Dean, et al.
Pageof 22